Pharma Mar SA
MAD:PHM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.24
81.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pharma Mar SA
Pharma Mar SA
Gross Profit
Pharma Mar SA
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharma Mar SA
MAD:PHM
|
Gross Profit
€157.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
3%
|
|
|
Grifols SA
MAD:GRF
|
Gross Profit
€2.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Oryzon Genomics SA
MAD:ORY
|
Gross Profit
-€1.1m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Biotechnology Assets SA
MAD:BST
|
Gross Profit
€2.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Pharma Mar SA
Glance View
Nestled in the vibrant biotech landscape of Spain, Pharma Mar SA emerges as a pioneer, weaving the wonders of the sea into groundbreaking medical therapies. Born from the vision of harnessing marine biodiversity, the company delves into the vast oceanic expanse, unearthing bioactive compounds with potential therapeutic uses. This oceanic pursuit forms the backbone of its innovative approach, focusing on oncological drugs derived from the depths of the sea. Their portfolio showcases significant breakthroughs, with products like Yondelis, originally discovered in a sea squirt, reflecting their unique niche in the drug development pipeline. By advancing these marine-based molecules through intensive clinical research, Pharma Mar translates the ocean's secrets into lifesaving treatments, underscoring its hallmark presence in oncology. The company ingeniously monetizes this frontier exploration by orchestrating a business model encompassing rigorous R&D, strategic partnerships, and licensing agreements. Pharma Mar invests heavily in its research, channeling substantial resources into both preclinical and clinical trials to elevate these marine compounds into market-ready drugs. Partnering with global pharmaceutical heavyweights enables them to extend their market reach while sharing development costs and multiplying revenue streams through royalties and milestone payments. Furthermore, licensing their findings expands their financial foothold, allowing them to reap returns on their intellectual exploits without the burden of full-scale commercialization. Pharma Mar’s adept navigation of the pharmaceutical seas has thus firmly anchored its place within the global biotech arena.
See Also
What is Pharma Mar SA's Gross Profit?
Gross Profit
157.7m
EUR
Based on the financial report for Sep 30, 2024, Pharma Mar SA's Gross Profit amounts to 157.7m EUR.
What is Pharma Mar SA's Gross Profit growth rate?
Gross Profit CAGR 10Y
3%
Over the last year, the Gross Profit growth was -1%. The average annual Gross Profit growth rates for Pharma Mar SA have been -3% over the past three years , 15% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet
